The ACT partner drug molecular surveyor is an interactive mapping tool that provides researchers and policy makers with an overview of the changes in the prevalence of molecular markers associated with malaria drug resistance over time and location. It helps to inform international, regional and national surveillance strategies. 

The ACT Partner Drug Molecular Surveyor

  • Summarises baseline data from more than 470 published and unpublished studies on molecular markers of antimalarial drug resistance between 2001 and 2017
  • Focuses on resistance markers for piperaquine (PPQ), amodiaquine (AQ), lumefantrine (LUM) and mefloquine (MQ) found in Plasmodium falciparum malaria parasite pfmdr1, pfcrt, and pfpm2 genes
  • Enables filtering of data based on antimalarial treatment type, resistance marker, country, sample size and time
  • Displays further detailed information about all the studies selected within the Surveyor in summary and reference tables
  • Allows downloads of data as a csv file
  • Permits you to view the study site and country by hovering the mouse cursor over a map pin. You can then click on the pin to view more detailed information about the study site, and click on the publication tab to view the associated publication within PubMed

 

Discover the methodology behind developing the Molecular Surveyor, and the Molecular Scientific Group and Informatics team that developed the tool.

Explore a previous version of the Molecular Surveyor displaying resistance markers for sulphadoxine pyrimethamine found on genes, dhfr and dhps

To find out how to contribute molecular data, ask us a question or work with our Molecular Scientific Group, please email molecular [at] wwarn [dot] org